一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> European Neuropsychopharmacology >>article
European Neuropsychopharmacology

European Neuropsychopharmacology

IF: 6.09
Download PDF

Agomelatine: A narrative review

Published:1 September 2011 DOI: 10.1016/j.euroneuro.2011.07.004 PMID: 21835598
Koen Demyttenaere

Abstract

Long-term antidepressant treatment success should be viewed as the result of the cumulative effects of treatment at each stage of major depressive disorder (MDD), and as a balance between efficacy and tolerability/safety. Depression is a heterogeneous disorder and different mechanisms of action of different antidepressants probably capitalize on this response heterogeneity. Results from clinical trials with agomelatine, a melatonergic receptor agonist (MT1/MT2) and 5HT2C receptor antagonist, have shown that it is efficacious in both the acute phase and the continuation phase of treatment of depression. Agomelatine's efficacy is observed in different depressive symptom clusters (core depression symptoms, sleep symptoms, anxiety, retardation, somatic symptoms, and work and activities). Active comparator trials show at least comparable efficacy with other antidepressants (paroxetine, venlafaxine, sertraline, fluoxetine) and efficacy has also been demonstrated in severe depression and in treating anxiety symptoms associated with major depression. The tolerability profile shows some clinically significant advantages especially in the lower incidence of treatment emergent sexual dysfunction and of weight gain, two adverse events experienced by patients as most bothersome. Transient aminotransferase elevations without clinical signs of liver damage have been observed more frequently than with placebo (1.1% versus 0.7%), and a hepatic monitoring schedule is therefore recommended.

Substances (8)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Agomelatine 138112-76-2 C15H17NO2 668 suppliers $5.00-$2500.00
Melanotan II 121062-08-6 C50H69N15O9 481 suppliers $35.00-$3154.84
Venlafaxine 93413-69-5 C17H27NO2 266 suppliers $10.00-$3100.00
Paroxetine 61869-08-7 C19H20FNO3 236 suppliers Inquiry
Fluoxetine 54910-89-3 C17H18F3NO 217 suppliers Inquiry
Sertraline 79617-96-2 C17H17Cl2N 187 suppliers Inquiry
Muscarinic toxin 1 25 suppliers $290.70-$3900.00
5HT2C Receptor peptide 6 suppliers Inquiry

Similar articles

IF:4.3

Pharmacological properties of baicalin on liver diseases: a narrative review.

ACS Applied Electronic Materials Jin-Yu Yang, Min Li,etc Published: 1 October 2021
IF:3.2

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Kidney Diseases Xiaoxiao Tang, Fei Liu,etc Published: 10 November 2023
IF:4.8

Current uses of chlorhexidine for management of oral disease: a narrative review

Journal of dentistry Zo? L.S. Brookes , Raul Bescos ,etc Published: 1 December 2020
湘潭县| 福泉市| 康乐县| 都安| 宜春市| 泌阳县| 西贡区| 岱山县| 潢川县| 宜春市| 平塘县| 桐梓县| 吴堡县| 龙游县| 新昌县| 铜鼓县| 台州市| 兴安盟| 新巴尔虎左旗| 鄄城县| 增城市| 宜春市| 手游| 昭觉县| 北流市| 于都县| 繁峙县| 登封市| 台安县| 双柏县| 曲阜市| 洪洞县| 瑞丽市| 偃师市| 大埔县| 基隆市| 河池市| 鄂尔多斯市| 北安市| 安陆市| 镇原县|